Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 11/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638967 | 0.89 | TGFBR1 (0.48) | TGFBR1TRPA1 | |
| SCHEMBL15639499 | 0.86 | TGFBR1 (0.53) | TGFBR1TRPA1ROCK2TRPM8 | |
| SCHEMBL15639504 | 0.86 | TGFBR1 (0.53) | TGFBR1TRPA1ROCK2TRPM8 | |
| SCHEMBL15639196 | 0.86 | TGFBR1 (0.53) | TGFBR1TRPA1TRPM8 | |
| SCHEMBL15637975 | 0.84 | TGFBR1 (0.51) | TGFBR1TRPA1ROCK2ROCK1TRPM8 | |
| SCHEMBL30117441 | 0.84 | TGFBR1 (0.51) | TGFBR1TRPA1ROCK2ROCK1TRPM8 | |
| SCHEMBL15639722 | 0.81 | TGFBR1 (0.72) | TGFBR1TRPA1ROCK2ROCK1TRPM8 | |
| SCHEMBL30117521 | 0.80 | TRPA1 (0.48) | TGFBR1TRPA1 | |
| SCHEMBL15638854 | 0.80 | TRPA1 (0.48) | TGFBR1TRPA1 | |
| SCHEMBL28425052 | 0.80 | TGFBR1 (0.71) | TGFBR1TRPA1ROCK2ROCK1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| EP-2903978-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | claimed |
| WO-2014055955-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160052909-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-02-25 | — | — | US | disclosed |
| WO-2015157093-A1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145433-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2903978-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107073-A1 | GDF-8 Inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2014055955-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107073-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TGFBR1 128/4885TRPA1 4474/4885ROCK2 500/4885 |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | TGFBR1 1/4885TRPA1 4073/4885ROCK2 416/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | TGFBR1 2/4885TRPA1 4082/4885ROCK2 202/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | TGFBR1 3/4885TRPA1 4202/4885ROCK2 267/4885 |
| US-20160052909-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | TGFBR1 128/4885TRPA1 4474/4885ROCK2 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.